SLC5A2 and hepatocellular carcinoma: We previously reported that the SGLT2 inhibitor empagliflozin showed anti-steatotic and anti-inflammatory effects [5], which suppressed the development of NASH in a mouse model of diabetes and NASH/cirrhosis/HCC (the STAM mouse) [10].